Our Noble Purpose

To advance the discovery and development of first-in-class, best-in-class antibody therapeutics to validated targets for unique and emerging markets with significant medical need.

Our Noble Purpose

To advance the discovery and development of first-in-class, best-in-class antibody therapeutics to validated targets for unique and emerging markets with significant medical need.

Home

Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best-in-class therapeutic antibodies with significant clinical and commercial differentiation.

News

June 5, 2017
Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial for Namacizumab; Generates Safety, Tolerability, and Pharmacokinetics Data; Prepares To Initiate Study in Non-Alcoholic Fatty Liver Disease Patients
February 16, 2017
In the News: Unique Antibody Therapeutic for NASH
Bird Rock Bio Receives Approval to Start First in Human Clinical Trial for Namacizumab, Enters Into Agreement with GE Healthcare for Process Development and Scale-up to Provide Clinical Phase 2 cGMP Material, and Enters into a Collaboration and Option Agreement with Janssen Pharmaceuticals, Inc.

Noteworthy

Bird Rock Bio, Inc. was founded quidam vocent in, dolores mediocrem periculis ad pri, at possit nominavi constituam vis